Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells.
IFN-alpha-2b, known as potent immune modulator, can either inhibit or enhance immune cell activity within the tightly regulated microenvironment of inflammation, depending upon the concentration of the cytokine and the activation stage of the cell. Chemokine receptors, which not only mediate chemotaxis of immune cells to the site of inflammation but also affect cellular activation by transferring corresponding signals, represent yet another level of immune regulation. Here we demonstrate that IFN-alpha increases the expression of CCR1 and CCR3 in primary mononuclear phagocytes, as well as in the monocytoid cell line U937. Enhanced receptor mRNA expression correlated with functional readouts such as increased intracellular calcium mobilization and cell migration in response to ligands. Expression of CCR2b, CCR4, CCR5, and CXCR4 was unchanged or decreased after IFN-alpha treatment. These observations indicate a differentially regulated cellular signaling relationship of IFN-alpha pathways and chemokine receptor expression. We also provide evidence that, under these conditions, IFN-alpha treatment increased the expression of CD95 (Fas, Apo1), resulting in enhanced susceptibility to apoptosis. Taken together, these data add important information for the rational application of IFN-alpha (2b) in immune and cancer therapies.
Zella
D
D
Institute of Human Virology, University of Maryland, Baltimore, MD 21201, USA.
Barabitskaja
O
O
Casareto
L
L
Romerio
F
F
Secchiero
P
P
Reitz
M S
MS
Gallo
R C
RC
Weichold
F F
FF
D017209:Apoptosis / Q000187:drug effects* / Q000276:immunology; D002118:Calcium / Q000378:metabolism; D002452:Cell Count / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D018946:Chemokine CCL5 / Q000378:metabolism; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology*; D007424:Intracellular Fluid / Q000378:metabolism; D008024:Ligands; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis; D054389:Receptors, CCR1; D054397:Receptors, CCR3; D019707:Receptors, Chemokine / Q000096:biosynthesis* / Q000502:physiology; D011994:Recombinant Proteins; D020298:U937 Cells; D019014:fas Receptor / Q000096:biosynthesis*
C515300:CCR1 protein, human; C515350:CCR3 protein, human; D018946:Chemokine CCL5; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008024:Ligands; D012333:RNA, Messenger; D054389:Receptors, CCR1; D054397:Receptors, CCR3; D019707:Receptors, Chemokine; D011994:Recombinant Proteins; D019014:fas Receptor; D002118:Calcium